Antibody-Drug Conjugates in Myeloid Leukemias

Targeted therapy in oncology brings with it the promise to maximize cancer cell cytotoxicity with minimal off-target effects. Antibody-drug conjugates (ADCs), an important group of such targeted agents, consist of a monoclonal antibody conjugated to a potent cytotoxic drug. In the field of leukemia, ADCs form an important component of therapeutic arsenal through the use of gemtuzumab ozogamicin in acute myeloid leukemia and inotuzumab ozogamicin (InO) in B-cell acute lymphoblastic leukemia, 2 approved agents. A recombinant fusion protein, tagraxofusp, which function similar to ADC, has gained approval for therapy in blastic plasmacytic dendritic cell neoplasm. The use of such agents as monotherapy or as part of a combination therapy has led to improved response rates and outcomes in certain specific disease subtypes and has led to further studies to identify novel cellular targets and improved delivery of cytotoxic agents using ADC. In this review, we will discuss about ADCs in myeloid leukemia and understand their development and current use in the field.

Automated summary

Targeted therapy with antibody-drug conjugates (ADCs) has shown promise in maximizing cancer cell cytotoxicity with minimal off-target effects. ADCs have been used in the treatment of specific subtypes of leukemia, leading to improved response rates and outcomes. Further research is being conducted to identify novel cellular targets and improve delivery of cytotoxic agents using ADCs.